STADA Arzneimittel AG — M&A Activity 2005

Dec 12, 2005

News Details

Ad-hoc | 12 December 2005 14:59

STADA: Product acquisitions(e.g. Mobilat) strengthen European brand business

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STADA Arzneimittel AG has concluded today, December 12, 2005, through agreements between various STADA subsidiaries and the SANKYO PHARMA Group Europe the purchase of a package of eleven European branded products. These products, which are positioned in various areas of indication and, mainly, in the OTC area, achieved Europe-wide sales in 2004 in a total amount of approx. EUR 38 million. Among the best known of these brands are Mobilat(R), with sales of approx. EUR 18 million and Hirudoid(R), with sales of approx. EUR 14 million – both of which are products for the treatment of blunt injuries such as contusions or sports injuries. The expenses for the acquisition of the entire product package amount to a total of EUR 82.0 million. Sales focuses of the acquired product package are in Germany, Italy, the United Kingdom and Belgium. In these countries, the acquired products can, following the transfer of the drug approvals to the individual STADA sales companies, be directly integrated into the existing sales structures. A further sales focus is Finland. There, STADA is taking over the existing sales organization with nine employees who sell the products via pharmacies from 2006. The agreements call for a staggered takeover of the various approvals and trade-marks until April, 2007. Over the course of the first half year of 2006, STADA will successively take over sales responsibility for the products in the individual national markets as soon as the drug approvals have been transferred there. The consolidation of the product sales in the Group will be staggered accordingly. It has, however, been secured in the contract that STADA can draw economic benefit from the entire product package from the time the agreements are signed. Further information: STADA Arzneimittel AG / Corporate Communications / Stadastrasse 2-18 / 61118 Bad Vilbel / Germany / Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de Or visit our website at http://www.stada.com ISIN: DE0007251803 (MDAX); (MDAX); DE0007251845; DE0001069540; DE0001069557 WKN: 725180; 725184; 106954; 106955 Listed: Amtlicher Markt in Düsseldorf und Frankfurt End of ad hoc announcement (c)DGAP 12.12.2005